Scios Launches Natrecor in United States New Drug Commercially Available in
Hospitals Nationwide One Week After FDA Approval
SUNNYVALE, Calif., Aug 22, 2001 /PRNewswire via COMTEX/ -- Scios Inc. (Nasdaq: SCIO) announced today that it has begun filling orders for and shipping Natrecor(R) (nesiritide) to U.S. hospitals and that the drug is now available for use nationwide. Scios also announced that the 165-person sales force is actively educating physicians and other relevant audiences about Natrecor.
"We have made Natrecor fully available in the United States just one week after receiving FDA approval, which demonstrates our sales and marketing preparedness and capability," said Richard B. Brewer, Scios' president and chief executive officer. "Wholesalers have been placing orders, numerous hospitals have received their first delivery, and we are getting reports back from physicians who have already begun using Natrecor to treat their patients."
Scios received FDA approval to market Natrecor(R) (nesiritide) in the United States on August 13, 2001.
Natrecor is the first of a new drug class, called human B-type natriuretic peptides (hBNP), to be made available as a therapeutic for human disease in the United States. Natrecor is a recombinant form of hBNP, a natural protein found in the body. |
